| Company Name: |
cjbscvictory |
| Tel: |
13348960310 13348960310 |
| Email: |
3003867561@qq.com |
|
| | BIIL 284 Basic information |
| Product Name: | BIIL 284 | | Synonyms: | BIIL 284;Amelubant
(BIIL284;Carbamic acid, N-[[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]phenyl]methoxy]phenyl]iminomethyl]-, ethyl ester;Amelubant | | CAS: | 346735-24-8 | | MF: | C33H34N2O5 | | MW: | 538.63 | | EINECS: | | | Product Categories: | | | Mol File: | 346735-24-8.mol |  |
| | BIIL 284 Chemical Properties |
| density | 1.15±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 9.83±0.46(Predicted) | | form | Solid | | color | White to off-white |
| | BIIL 284 Usage And Synthesis |
| Uses | Amelubant (BIIL 284) is a potent, oral and long acting LTB4 receptor antagonist, negligibly binds to LTB4 receptor, with Kis of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a proagent of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity[1]. | | IC 50 | LTB4: 221 nM (Ki, in vital human granulocytes); LTB4: 230 nM (Ki, in cell membranes) | | References | [1] Birke FW, et al. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther. 2001 Apr;297(1):458-66. PMID:11259574 |
| | BIIL 284 Preparation Products And Raw materials |
|